Intelligence / Healthtech / New Clinical Trials / Pfizer
Pfizer
4 Nov 2026: Trial registered · A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 4 Nov 2026
- Title
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
- Conditions
- Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07915609
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Pfizer
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Pfizer in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.